{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:11:40Z","timestamp":1785769900710,"version":"3.56.0"},"reference-count":146,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Research Grants Council-General Research Fund","award":["14110625"],"award-info":[{"award-number":["14110625"]}]},{"name":"CUHK Knowledge Transfer Committee-IdeaBooster Fund","award":["IDBF25MED10"],"award-info":[{"award-number":["IDBF25MED10"]}]},{"DOI":"10.13039\/501100004853","name":"CUHK","doi-asserted-by":"publisher","award":["2026.181"],"award-info":[{"award-number":["2026.181"]}],"id":[{"id":"10.13039\/501100004853","id-type":"DOI","asserted-by":"publisher"}]},{"award":["2026.181"],"award-info":[{"award-number":["2026.181"]}],"id":[{"id":"https:\/\/ror.org\/00t33hh48","id-type":"ROR","asserted-by":"publisher"}]},{"name":"United College Endowment Fund Research","award":["8509804"],"award-info":[{"award-number":["8509804"]}]},{"award":["8509804"],"award-info":[{"award-number":["8509804"]}],"id":[{"id":"https:\/\/ror.org\/0229evh14","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Late-stage cutaneous melanoma management has already evolved into systemic therapy thanks to the fast development of novel targeted inhibitors and immune checkpoint blockers. Therefore, a reliable prediction of systemic therapy response became crucial for making a personalised management plan for melanoma patients. Although there are multiple biomarkers already available, the overall predictive confidence remains low due to heterogeneous responses among patients. Therefore, novel solid predictive biomarkers are still greatly needed. With the development of new technologies and artificial intelligence, new predictive models are being proposed and generated. In this review, we thoroughly evaluated the established biomarkers that are already in use for clinical practice. In addition, we proposed the emerging new markers with great potential by critically reviewing the literature. Furthermore, we proposed a future framework for making a tailored clinical management plan for melanoma patients.<\/jats:p>","DOI":"10.3390\/cancers18152487","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:16:27Z","timestamp":1785766587000},"page":"2487","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predictive Biomarkers of Systemic Therapy Response in Cutaneous Melanoma"],"prefix":"10.3390","volume":"18","author":[{"given":"U Sin","family":"Wong","sequence":"first","affiliation":[{"name":"Department of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong"},{"name":"Li Ka Shing Institute of Health Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5856-5854","authenticated-orcid":false,"given":"Dajiang","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong"},{"name":"Li Ka Shing Institute of Health Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.1200\/JCO.23.01136","article-title":"Systemic Therapy for Melanoma: ASCO Guideline Update","volume":"41","author":"Seth","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Hui, S.Y., Jain, R., Haass, N.K., Weninger, W., Tikoo, S., and Guo, D. (2026). The Emerging Melanoma Management: Historical Perspective to Future Directions. Cancers, 18.","DOI":"10.3390\/cancers18060968"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/s43018-025-01113-y","article-title":"Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: Cohort A of the phase 2 SWOG S1512 trial","volume":"7","author":"Kendra","year":"2026","journal-title":"Nat. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41591-024-03411-x","article-title":"Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB\u2013D melanoma: A phase 1\/2 trial","volume":"31","author":"Dummer","year":"2025","journal-title":"Nat. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1038\/s41591-025-03967-2","article-title":"Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: The randomized phase 1b\/2 Morpheus-Melanoma trial","volume":"31","author":"Long","year":"2025","journal-title":"Nat. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1038\/s41467-024-45798-8","article-title":"Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: The Phase II NeoACTIVATE trial","volume":"15","author":"Hieken","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJMoa2504966","article-title":"Nivolumab for Resected Stage III or IV Melanoma at 9 Years","volume":"394","author":"Ascierto","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1158\/2159-8290.CD-21-1141","article-title":"Adjuvant Pembrolizumab versus IFN\u03b12b or Ipilimumab in Resected High-Risk Melanoma","volume":"12","author":"Grossmann","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant Dabrafenib plus Trametinib in Stage III BRAF -Mutated Melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1200\/JCO-25-01346","article-title":"RP1 Combined With Nivolumab in Advanced Anti\u2013PD-1\u2013Failed Melanoma (IGNYTE)","volume":"43","author":"Wong","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1038\/s41467-026-69629-0","article-title":"LOAd703-induced tumor microenvironment gene engineering in combination with atezolizumab in metastatic malignant melanoma: A phase I\/II trial","volume":"17","author":"Hamid","year":"2026","journal-title":"Nat. Commun."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.trecan.2024.04.003","article-title":"Lifileucel: The first cellular therapy approved for solid tumours","volume":"10","author":"Julve","year":"2024","journal-title":"Trends Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e012659","DOI":"10.1136\/jitc-2025-012659","article-title":"Improved survival in advanced melanoma patients treated with fecal microbiota transplantation using healthy donor stool in combination with anti-PD1: Final results of the MIMic phase 1 trial","volume":"13","author":"Hadi","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/s41591-025-04186-5","article-title":"Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: The phase 2 FMT-LUMINate trial","volume":"32","author":"Duttagupta","year":"2026","journal-title":"Nat. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1158\/2159-8290.CD-24-0158","article-title":"T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study","volume":"14","author":"Gainor","year":"2024","journal-title":"Cancer Discov."},{"key":"ref_17","unstructured":"Wilmott, J. (2026, July 01). Personalised Immunotherapy Platform (PIP-PREDICT) [Clinical Trial: NCT06536257], Available online: https:\/\/clinicaltrials.gov\/study\/NCT06536257."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/modpathol.2017.104","article-title":"Molecular testing for BRAF mutations to inform melanoma treatment decisions: A move toward precision medicine","volume":"31","author":"Cheng","year":"2018","journal-title":"Mod. Pathol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1038\/s41467-024-47425-y","article-title":"Molecular patterns of resistance to immune checkpoint blockade in melanoma","volume":"15","author":"Lauss","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1038\/s41467-023-36979-y","article-title":"The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma","volume":"14","author":"Lim","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Castellani, G., Buccarelli, M., Arasi, M.B., Rossi, S., Pisanu, M.E., Bellenghi, M., Lintas, C., and Tabolacci, C. (2023). BRAF Mutations in Melanoma: Biological Aspects, Therapeutic Implications, and Circulating Biomarkers. Cancers, 15.","DOI":"10.3390\/cancers15164026"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/s41591-018-0157-9","article-title":"Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma","volume":"24","author":"Auslander","year":"2018","journal-title":"Nat. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s40268-024-00475-5","article-title":"Targeting Non-V600 Mutations in BRAF: A Single Institution Retrospective Analysis and Review of the Literature","volume":"24","author":"Chaudhary","year":"2024","journal-title":"Drugs R&D"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"115703","DOI":"10.1016\/j.ejca.2025.115703","article-title":"Targeted therapy for rare BRAF-mutated melanoma: Updated multicenter analysis and launch of a publicly accessible online outcome database","volume":"228","author":"Menzer","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.pathol.2023.11.004","article-title":"Prognostic and predictive biomarkers in melanoma","volume":"56","author":"Maher","year":"2024","journal-title":"Pathology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1001\/jamaoncol.2015.0493","article-title":"Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma","volume":"1","author":"Thomas","year":"2015","journal-title":"JAMA Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1158\/0008-5472.CAN-18-2711","article-title":"A Functional Landscape of Resistance to MEK1\/2 and CDK4\/6 Inhibition in NRAS-Mutant Melanoma","volume":"79","author":"Hayes","year":"2019","journal-title":"Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s43856-025-00932-5","article-title":"Suppression of NRAS-mutant melanoma growth with NRAS-targeting Antisense Oligonucleotide treatment reveals therapeutically relevant kinase co-dependencies","volume":"5","author":"Feichtenschlager","year":"2025","journal-title":"Commun. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1200\/JCO-24-02595","article-title":"BO-112 Plus Pembrolizumab for Patients With Anti\u2013PD-1\u2013Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203","volume":"43","author":"Dutriaux","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/s41591-025-04158-9","article-title":"Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial","volume":"32","author":"Hoeijmakers","year":"2026","journal-title":"Nat. Med."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Sorroche, B.P., Teixeira, R.d.J., Pereira, C.A.D., Santana, I.V.V., Vujanovic, L., Vazquez, V.d.L., and Arantes, L.M.R.B. (2023). PD-L1 Tumor Expression as a Predictive Biomarker of Immune Checkpoint Inhibitors\u2019 Response and Survival in Advanced Melanoma Patients in Brazil. Diagnostics, 13.","DOI":"10.3390\/diagnostics13061041"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"850","DOI":"10.7150\/jca.81899","article-title":"Recent Advancement of PD-L1 Detection Technologies and Clinical Applications in the Era of Precision Cancer Therapy","volume":"14","author":"Zhang","year":"2023","journal-title":"J. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Puglisi, R., Bellenghi, M., Pontecorvi, G., Pallante, G., Car\u00e8, A., and Mattia, G. (2021). Biomarkers for Diagnosis, Prognosis and Response to Immunotherapy in Melanoma. Cancers, 13.","DOI":"10.3390\/cancers13122875"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41698-025-01250-8","article-title":"Predicting anti-PD-1 immune checkpoint blockade response in melanoma patients with spatially aware machine learning models","volume":"10","author":"Pybus","year":"2026","journal-title":"npj Precis. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1200\/JCO.24.01124","article-title":"Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047","volume":"43","author":"Tawbi","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"115547","DOI":"10.1016\/j.ejca.2025.115547","article-title":"Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year update","volume":"225","author":"Lipson","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2303175","DOI":"10.1002\/advs.202303175","article-title":"Challenges Coexist with Opportunities: Spatial Heterogeneity Expression of PD-L1 in Cancer Therapy","volume":"11","author":"Wang","year":"2024","journal-title":"Adv. Sci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41698-025-01230-y","article-title":"Prospective tumour mutation burden and neoantigen profiling predicts immunotherapy response in metastatic melanoma","volume":"10","author":"Mao","year":"2026","journal-title":"npj Precis. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e2500886","DOI":"10.1200\/PO-25-00886","article-title":"Molecular Profiling and Matched Targeted Therapy for Patients With Advanced Melanoma: Results From Part 1 of the MatchMEL Study","volume":"10","author":"Boutros","year":"2026","journal-title":"JCO Precis. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s44178-024-00121-9","article-title":"Advances in predictive biomarkers for melanoma immunotherapy","volume":"3","author":"Ma","year":"2024","journal-title":"Holist. Integr. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1038\/s41416-026-03394-1","article-title":"Genetic landscape of stage II melanoma identifies CBL as a new driver gene and prognostic biomarker","volume":"134","author":"Lindner","year":"2026","journal-title":"Br. J. Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.cell.2024.02.041","article-title":"Cancer biomarkers: Emerging trends and clinical implications for personalized treatment","volume":"187","author":"Passaro","year":"2024","journal-title":"Cell"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13046-025-03637-8","article-title":"GLUT1 expression, lymphocyte distribution and CD3+ T-cell metabolic subsets as predictive markers of response to immunotherapy in advanced melanoma","volume":"45","author":"Paver","year":"2026","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","article-title":"Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab","volume":"171","author":"Riaz","year":"2017","journal-title":"Cell"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"15","DOI":"10.17305\/bjbms.2022.7953","article-title":"PD-L1 testing by immunohistochemistry in immuno-oncology","volume":"23","author":"Vranic","year":"2023","journal-title":"Biomol. Biomed."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e2303978120","DOI":"10.1073\/pnas.2303978120","article-title":"Invasion-Block and S-MARVEL: A high-content screening and image analysis platform identifies ATM kinase as a modulator of melanoma invasion and metastasis","volume":"120","author":"Guo","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/CMR.0000000000000298","article-title":"Microsatellite instability in melanoma: A comprehensive review","volume":"26","year":"2016","journal-title":"Melanoma Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41568-024-00705-7","article-title":"Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours","volume":"24","author":"Holder","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"12997","DOI":"10.1038\/s41598-021-92430-6","article-title":"Serum lactate dehydrogenase activities as systems biomarkers for 48 types of human diseases","volume":"11","author":"Wu","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Zhou, Y., Qi, M., and Yang, M. (2022). Current Status and Future Perspectives of Lactate Dehydrogenase Detection and Medical Implications: A Review. Biosensors, 12.","DOI":"10.3390\/bios12121145"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1731942","DOI":"10.1080\/2162402X.2020.1731942","article-title":"Lactate dehydrogenase: A marker of diminished antitumor immunity","volume":"9","author":"Koornstra","year":"2020","journal-title":"Oncoimmunology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ejca.2022.11.032","article-title":"Rationale for LDH-targeted cancer immunotherapy","volume":"181","author":"Miholjcic","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"7478","DOI":"10.1038\/s41598-020-63441-6","article-title":"Predicting circulating biomarker response and its impact on the survival of advanced melanoma patients treated with adjuvant therapy","volume":"10","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11523-021-00792-8","article-title":"Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors","volume":"16","author":"Gassenmaier","year":"2021","journal-title":"Target. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1080\/14737140.2018.1489246","article-title":"The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: Implications for melanoma treatment and care","volume":"18","author":"Keung","year":"2018","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/bjc.2015.467","article-title":"Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma","volume":"114","author":"Diem","year":"2016","journal-title":"Br. J. Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1080\/14737159.2024.2347484","article-title":"Prognostic biomarkers in melanoma: A 2023 update from clinical trials in different therapeutic scenarios","volume":"24","author":"Roccuzzo","year":"2024","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1586\/17469872.3.5.569","article-title":"Current concepts of metastasis in melanoma","volume":"3","author":"Zbytek","year":"2008","journal-title":"Expert Rev. Dermatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"vi8","DOI":"10.1093\/annonc\/mdp251","article-title":"Biomarkers in melanoma","volume":"20","author":"Gogas","year":"2009","journal-title":"Ann. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Janka, E.A., V\u00e1rv\u00f6lgyi, T., Sipos, Z., So\u00f3s, A., Hegyi, P., Kiss, S., Dembrovszky, F., Csupor, D., K\u00e9ringer, P., and P\u00e9csi, D. (2021). Predictive Performance of Serum S100B Versus LDH in Melanoma Patients: A Systematic Review and Meta-Analysis. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.772165"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"108442","DOI":"10.1016\/j.ejso.2024.108442","article-title":"Reconsidering S100B: Why it is time to abandon its use in detecting disease recurrence in stage III melanoma patients","volume":"50","author":"Jansen","year":"2024","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"116676","DOI":"10.1016\/j.ejca.2026.116676","article-title":"Translating ctDNA into cutaneous melanoma care: An international expert survey","volume":"239","author":"Geidel","year":"2026","journal-title":"Eur. J. Cancer"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1200\/JCO.2013.49.8691","article-title":"Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma","volume":"31","author":"Ascierto","year":"2013","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1158\/1078-0432.CCR-15-0321","article-title":"Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials","volume":"22","author":"Gagnon","year":"2016","journal-title":"Clin. Cancer Res. An. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Charbel, N., Rizkallah, J., Bal, M.N., El Masri, A., Armache, E., Ghezzawi, M., Awada, A., Kreidieh, L., Mehdi, J., and Kreidieh, F. (2026). Circulating Tumor DNA in Melanoma: Advances in Detection, Clinical Applications, and Integration with Emerging Technologies. Int. J. Mol. Sci., 27.","DOI":"10.3390\/ijms27031569"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e005292","DOI":"10.1136\/jitc-2022-005292","article-title":"Artificial intelligence and radiomics: Fundamentals, applications, and challenges in immunotherapy","volume":"10","author":"Dercle","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"9577","DOI":"10.1200\/JCO.2024.42.16_suppl.9577","article-title":"Use of early circulating tumour DNA dynamics in patients with stage III melanoma receiving neoadjuvant combination immunotherapy","volume":"42","author":"Chan","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e2500119","DOI":"10.1200\/OA-25-00119","article-title":"Sensitivity of Circulating Tumor DNA for Detection of Minimal Residual Disease Recurrence or Relapse in Patients With Melanoma","volume":"3","author":"Steimle","year":"2026","journal-title":"JCO Oncol. Adv."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"6233904","DOI":"10.1155\/2022\/6233904","article-title":"Evaluating the Diagnostic Potentials of Circulating Tumor DNA against Melanoma: A Systematic Review and Meta-Analysis","volume":"2022","author":"Zhang","year":"2022","journal-title":"J. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"S264","DOI":"10.1016\/j.annonc.2025.08.607","article-title":"173TiP DyNAMIc trial: Circulating tumour DNA guided adaptive BRAF and MEK inhibitor therapy\u2014A phase II randomised proof of concept study","volume":"36","author":"Lee","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"TPS9603","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS9603","article-title":"DETECTION phase II\/III trial: Circulating tumor DNA\u2013guided therapy for stage IIB\/C melanoma after surgical resection","volume":"40","author":"Lee","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Chan, W.Y., Stewart, A., Diefenbach, R.J., Gray, E.S., Lee, J.H., Scolyer, R.A., Long, G.V., and Rizos, H. (2025). Pre-Amplification of Cell-Free DNA: Balancing Amplification Errors with Enhanced Sensitivity. Biomolecules, 15.","DOI":"10.3390\/biom15060883"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13046-025-03322-w","article-title":"A scoping review of factors influencing the implementation of liquid biopsy for cancer care","volume":"44","author":"Sheriff","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1093\/annonc\/mdz048","article-title":"Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA","volume":"30","author":"Tan","year":"2019","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e154941","DOI":"10.1172\/JCI154941","article-title":"Circulating tumor DNA: Current challenges for clinical utility","volume":"132","author":"Dang","year":"2022","journal-title":"J. Clin. Investig."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41571-020-00457-x","article-title":"Liquid biopsy enters the clinic\u2014Implementation issues and future challenges","volume":"18","author":"Ignatiadis","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1158\/1078-0432.CCR-19-3015","article-title":"Harmonizing Cell-Free DNA Collection and Processing Practices through Evidence-Based Guidance","volume":"26","author":"Greytak","year":"2020","journal-title":"Clin. Cancer Res. An. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1093\/clinchem\/hvaa164","article-title":"Generic Protocols for the Analytical Validation of Next-Generation Sequencing-Based ctDNA Assays: A Joint Consensus Recommendation of the BloodPAC\u2019s Analytical Variables Working Group","volume":"66","author":"Godsey","year":"2020","journal-title":"Clin. Chem."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s12094-025-04024-7","article-title":"Dynamic blood-based biomarkers predict early response to ipilimumab and nivolumab in advanced melanoma","volume":"28","author":"Acar","year":"2025","journal-title":"Clin. Transl. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"FSO608","DOI":"10.2144\/fsoa-2020-0070","article-title":"A retrospective analysis of eosinophilia as a predictive marker of response and toxicity to cancer immunotherapy","volume":"6","author":"Krishnan","year":"2020","journal-title":"Future Sci. OA"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"108613","DOI":"10.1016\/j.pharmthera.2024.108613","article-title":"Immunotherapy in melanoma: Can we predict response to treatment with circulating biomarkers?","volume":"256","author":"Splendiani","year":"2024","journal-title":"Pharmacol. Ther."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Xu, Y., Fu, Y., Zhu, B., Wang, J., and Zhang, B. (2020). Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.02023"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/jjco\/hyy201","article-title":"Correlation between blood cell count and outcome of melanoma patients treated with anti-PD-1 antibodies","volume":"49","author":"Nakamura","year":"2019","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1634\/theoncologist.2018-0563","article-title":"Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors","volume":"24","author":"Pavan","year":"2019","journal-title":"Oncologist"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1172\/JCI96798","article-title":"Early B cell changes predict autoimmunity following combination immune checkpoint blockade","volume":"128","author":"Das","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1158\/1078-0432.CCR-18-2795","article-title":"Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1-Based Immunotherapy","volume":"25","author":"Lim","year":"2019","journal-title":"Clin. Cancer Res. An. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/ijc.30498","article-title":"D-dimers in malignant melanoma: Association with prognosis and dynamic variation in disease progress","volume":"140","author":"Desch","year":"2017","journal-title":"Int. J. Cancer"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1038\/s41591-022-01965-2","article-title":"Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome","volume":"28","author":"Simpson","year":"2022","journal-title":"Nat. Med."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Prka\u010din, I., Mokos, M., Ferara, N., and \u0160itum, M. (2024). Melanoma\u2019s New Frontier: Exploring the Latest Advances in Blood-Based Biomarkers for Melanoma. Cancers, 16.","DOI":"10.3390\/cancers16244219"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Spiliopoulou, P., Holanda Lopes, C.D., and Spreafico, A. (2023). Promising and Minimally Invasive Biomarkers: Targeting Melanoma. Cells, 13.","DOI":"10.3390\/cells13010019"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s40364-023-00540-2","article-title":"Extracellular vesicle-based liquid biopsy biomarkers and their application in precision immuno-oncology","volume":"11","author":"Asleh","year":"2023","journal-title":"Biomark. Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"732","DOI":"10.21037\/tcr.2019.04.25","article-title":"RAB27A-mediated melanoma exosomes: Promoters of invasion and metastasis","volume":"8","author":"Guo","year":"2019","journal-title":"Transl. Cancer Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1002\/ijc.32064","article-title":"RAB27A promotes melanoma cell invasion and metastasis via regulation of pro-invasive exosomes","volume":"144","author":"Guo","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.jid.2019.12.023","article-title":"RAB27A\/Melanophilin Blocker Inhibits Melanoma Cell Motility and Invasion","volume":"140","author":"Guo","year":"2020","journal-title":"J. Investig. Dermatol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/pcmr.12903","article-title":"Abrogation of RAB27A expression transiently affects melanoma cell proliferation","volume":"33","author":"Guo","year":"2020","journal-title":"Pigment Cell Melanoma Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41586-018-0392-8","article-title":"Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response","volume":"560","author":"Chen","year":"2018","journal-title":"Nature"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13045-023-01452-2","article-title":"Exosomal circRNA: Emerging insights into cancer progression and clinical application potential","volume":"16","author":"Zhang","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"V\u00e1rv\u00f6lgyi, T., Janka, E.A., Sz\u00e1sz, I., Koroknai, V., Toka-Farkas, T., Szab\u00f3, I.L., V\u00e1nyai, B., Szegedi, A., Emri, G., and Bal\u00e1zs, M. (2023). Combining Biomarkers for the Diagnosis of Metastatic Melanoma. J. Clin. Med., 13.","DOI":"10.3390\/jcm13010174"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/s41698-024-00534-9","article-title":"A whirl of radiomics-based biomarkers in cancer immunotherapy, why is large scale validation still lacking?","volume":"8","author":"Ligero","year":"2024","journal-title":"npj Precis. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Mubin, N., Alnukhali, M., Ahmad, N., Driscoll, J.J., and Ahmad, A. (2026). Multidimensional tumor heterogeneity and its role in therapeutic resistance. Front. Immunol., 17.","DOI":"10.3389\/fimmu.2026.1794130"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Al Hmada, Y., Brodell, R.T., Kharouf, N., Flanagan, T.W., Alamodi, A.A., Hassan, S.-Y., Shalaby, H., Hassan, S.-L., Haikel, Y., and Megahed, M. (2024). Mechanisms of Melanoma Progression and Treatment Resistance: Role of Cancer Stem-like Cells. Cancers, 16.","DOI":"10.3390\/cancers16020470"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1007\/s11864-024-01279-0","article-title":"Advances in Understanding Drug Resistance Mechanisms and Innovative Clinical Treatments for Melanoma","volume":"25","author":"He","year":"2024","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12943-025-02294-x","article-title":"Dual role of interferon-gamma in the response of melanoma patients to immunotherapy with immune checkpoint inhibitors","volume":"24","author":"Wawrzyniak","year":"2025","journal-title":"Mol. Cancer"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"105308","DOI":"10.1016\/j.ebiom.2024.105308","article-title":"Single-cell RNA sequencing reveals melanoma cell state-dependent heterogeneity of response to MAPK inhibitors","volume":"107","author":"Lim","year":"2024","journal-title":"eBioMedicine"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Hegyi, B., Csik\u00f3, K., Balatoni, T., Fr\u00f6hlich, G., B\u0151cs, K., T\u00f3th, E., Mohos, A., Neumark, A., Menyh\u00e1rt, C., and Ferrone, S. (2024). Tumor-Infiltrating Immune Cells and HLA Expression as Potential Biomarkers Predicting Response to PD-1 Inhibitor Therapy in Stage IV Melanoma Patients. Biomolecules, 14.","DOI":"10.3390\/biom14121609"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Damiano, O.M., Stevens, A.J., Kenwright, D.N., and Seddon, A.R. (2025). Chronic Inflammation to Cancer: The Impact of Oxidative Stress on DNA Methylation. Front. Biosci.-Landmark, 30.","DOI":"10.31083\/FBL26142"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"4814","DOI":"10.1038\/s41388-025-03624-5","article-title":"From concept to clinic: A roadmap for DNA methylation biomarkers in liquid biopsies","volume":"44","author":"Pharo","year":"2025","journal-title":"Oncogene"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"30710","DOI":"10.1038\/s41598-025-13952-x","article-title":"The epiMelanoma test enables plasma-based detection of melanoma and prediction of immunotherapy response","volume":"15","author":"Dumas","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"217638","DOI":"10.1016\/j.canlet.2025.217638","article-title":"Pre-treatment DNA methylome and transcriptome profiles correlate with melanoma response to anti-PD1 immunotherapy","volume":"618","author":"Hossain","year":"2025","journal-title":"Cancer Lett."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13148-025-01865-5","article-title":"DNA methylation in melanoma immunotherapy: Mechanisms and therapeutic opportunities","volume":"17","author":"Deshmukh","year":"2025","journal-title":"Clin. Epigenet."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"201566","DOI":"10.1016\/j.humgen.2026.201566","article-title":"MicroRNAs in melanoma progression and metastasis: From mechanisms to therapy resistance","volume":"48","author":"Ellakwa","year":"2026","journal-title":"Hum. Gene"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12943-025-02298-7","article-title":"Circulating MicroRNAs: Functional biomarkers for melanoma prognosis and treatment","volume":"24","author":"Lim","year":"2025","journal-title":"Mol. Cancer"},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Caraviello, C., Nazzaro, G., Tavoletti, G., Boggio, F., Denaro, N., Murgia, G., Passoni, E., Benzecry Mancin, V., and Marzano, A.V. (2025). Melanoma Skin Cancer: A Comprehensive Review of Current Knowledge. Cancers, 17.","DOI":"10.3390\/cancers17172920"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/cncy.22829","article-title":"The role of the ThyGeNEXT oncogene panel used in combination with the expanded miRNA panel ThyraMIRv2 in Indeterminate thyroid nodules: A large, blinded, real-world, observational study","volume":"132","author":"Verma","year":"2024","journal-title":"Cancer Cytopathol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1038\/s41591-025-03699-3","article-title":"Inherited mitochondrial genetics as a predictor of immune checkpoint inhibition efficacy in melanoma","volume":"31","author":"Monson","year":"2025","journal-title":"Nat. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"e35897","DOI":"10.1002\/cncr.35897","article-title":"Mitochondrial proteome landscape unveils key insights into melanoma severity and treatment strategies","volume":"131","author":"Kim","year":"2025","journal-title":"Cancer"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1016\/j.jid.2021.12.012","article-title":"Evaluation of Plasma IL-6 in Patients with Melanoma as a Prognostic and Checkpoint Immunotherapy Predictive Biomarker","volume":"142","author":"Wang","year":"2022","journal-title":"J. Investig. Dermatol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1093\/annonc\/mdx190","article-title":"Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients","volume":"28","author":"Sanmamed","year":"2017","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/s41591-020-0856-x","article-title":"Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors","volume":"26","author":"Schalper","year":"2020","journal-title":"Nat. Med."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1038\/s43018-023-00610-2","article-title":"Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma","volume":"4","author":"Zimmer","year":"2023","journal-title":"Nat. Cancer"},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Gil, M., and Kim, K.E. (2019). Interleukin-18 Is a Prognostic Biomarker Correlated with CD8+ T Cell and Natural Killer Cell Infiltration in Skin Cutaneous Melanoma. J. Clin. Med., 8.","DOI":"10.3390\/jcm8111993"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1873585","DOI":"10.1080\/2162402X.2021.1873585","article-title":"Inflammatory B cells correlate with failure to checkpoint blockade in melanoma patients","volume":"10","author":"Lourenco","year":"2021","journal-title":"OncoImmunology"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1186\/s12935-025-04067-4","article-title":"Circulating IFN\u03b3-associated protein signatures predict response to neoadjuvant immunotherapy in patients with stage III melanoma","volume":"25","author":"Yang","year":"2025","journal-title":"Cancer Cell Int."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Lapeikis, I., and Urbonas, V. (2026). Circulating Cytokines in Melanoma Prognosis: Current Evidence and Future Perspectives. Medicina, 62.","DOI":"10.20944\/preprints202603.0352.v1"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"e20221952","DOI":"10.1084\/jem.20221952","article-title":"IFN-\u03b3 signature enables selection of neoadjuvant treatment in patients with stage III melanoma","volume":"220","author":"Reijers","year":"2023","journal-title":"J. Exp. Med."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Ou, G., Gou, J., Ou, H., Zheng, H., Zhu, Y., Li, J., and Liu, X. (2025). Gut markers for metastatic melanoma receiving immunotherapy. BMC Cancer, 25.","DOI":"10.1186\/s12885-025-14467-4"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1111\/exd.14639","article-title":"The gut microbiome and melanoma: A review","volume":"31","author":"Makaranka","year":"2022","journal-title":"Exp. Dermatol."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Dora, D., Bokhari, S.M.Z., Aloss, K., Takacs, P., Desnoix, J.Z., Szklen\u00e1rik, G., Hurley, P.D., and Lohinai, Z. (2023). Implication of the Gut Microbiome and Microbial-Derived Metabolites in Immune-Related Adverse Events: Emergence of Novel Biomarkers for Cancer Immunotherapy. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24032769"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11912-026-01744-z","article-title":"Toward Microbiome-Informed Melanoma Care: The Gut Microbiota in Melanoma Evolution, Immunotherapy Response and Immune-Related Toxicity","volume":"28","author":"Ziogas","year":"2026","journal-title":"Curr. Oncol. Rep."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Kokenberger, G., Singh, J., Hurd, D., Yu, T., Meng, X., Nguyen, M., Storkus, W.J., McKay, W., Luke, J.J., and Najjar, Y.G. (2025). Multiregional CT Features Improve Prediction of Immunotherapy Response in Advanced Melanoma. medRxiv.","DOI":"10.1101\/2025.10.26.25338837"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"e009568","DOI":"10.1136\/jitc-2024-009568","article-title":"Radiomic analysis of patient and interorgan heterogeneity in response to immunotherapies and BRAF-targeted therapy in metastatic melanoma","volume":"13","author":"Tompkins","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"18795","DOI":"10.1038\/s41598-021-98310-3","article-title":"FDG PET biomarkers for prediction of survival in metastatic melanoma prior to anti-PD1 immunotherapy","volume":"11","author":"Flaus","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/s41571-024-00891-1","article-title":"Multiparametric MRI for characterization of the tumour microenvironment","volume":"21","author":"Hoffmann","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"McGale, J., Hama, J., Yeh, R., Vercellino, L., Sun, R., Lopci, E., Ammari, S., and Dercle, L. (2023). Artificial Intelligence and Radiomics: Clinical Applications for Patients with Advanced Melanoma Treated with Immunotherapy. Diagnostics, 13.","DOI":"10.3390\/diagnostics13193065"},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Filippi, L., Bianconi, F., Schillaci, O., Spanu, A., and Palumbo, B. (2022). The Role and Potential of 18F-FDG PET\/CT in Malignant Melanoma: Prognostication, Monitoring Response to Targeted and Immunotherapy, and Radiomics. Diagnostics, 12.","DOI":"10.3390\/diagnostics12040929"},{"key":"ref_138","first-page":"e10047","article-title":"What\u2019s the Risk: Differentiating Risk Ratios, Odds Ratios, and Hazard Ratios?","volume":"12","author":"George","year":"2020","journal-title":"Cureus"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41540-025-00519-9","article-title":"Effective integration of multi-omics with prior knowledge to identify biomarkers via explainable graph neural networks","volume":"11","author":"Tripathy","year":"2025","journal-title":"npj Syst. Biol. Appl."},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Dippel, J., Preni\u00dfl, N., Hense, J., Liznerski, P., Winterhoff, T., Schallenberg, S., Kloft, M., Buchstab, O., Horst, D., and Alber, M. (2024). AI-Based Anomaly Detection for Clinical-Grade Histopathological Diagnostics. NEJM AI, 1.","DOI":"10.1056\/AIoa2400468"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.16.00009","article-title":"Circulating Tumor DNA Analysis and Functional Imaging Provide Complementary Approaches for Comprehensive Disease Monitoring in Metastatic Melanoma","volume":"1","author":"Wong","year":"2017","journal-title":"JCO Precis. Oncol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ebiom.2019.09.023","article-title":"Leveraging transcriptional dynamics to improve BRAF inhibitor responses in melanoma","volume":"48","author":"Smalley","year":"2019","journal-title":"EBioMedicine"},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Lau, D., Gar\u00e7on, F., Chandra, A., Lechermann, L.M., Aloj, L., Chilvers, E.R., Corrie, P.G., Okkenhaug, K., and Gallagher, F.A. (2020). Intravital Imaging of Adoptive T-Cell Morphology, Mobility and Trafficking Following Immune Checkpoint Inhibition in a Mouse Melanoma Model. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.01514"},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Gschwind, A., and Ossowski, S. (2025). AI Model for Predicting Anti-PD1 Response in Melanoma Using Multi-Omics Biomarkers. Cancers, 17.","DOI":"10.20944\/preprints202501.0904.v1"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"10095","DOI":"10.1038\/s41467-025-65051-0","article-title":"Multimodal AI and tumour microenvironment integration predicts metastasis in cutaneous melanoma","volume":"16","author":"Andrew","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"9541","DOI":"10.1200\/JCO.2025.43.16_suppl.9541","article-title":"AI-detected tumor-infiltrating lymphocytes and response to PD-1 based treatment in advanced melanoma","volume":"43","author":"Schuiveling","year":"2025","journal-title":"J. Clin. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/15\/2487\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:23:10Z","timestamp":1785766990000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/15\/2487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":146,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["cancers18152487"],"URL":"https:\/\/doi.org\/10.3390\/cancers18152487","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]}}}